No Data
No Data
Purple Biotech Eyes Key 2024 Milestones
Express News | HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $10 Price Target
Purple Biotech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 2399.38% HC Wainwright & Co. $10 → $10 Reiterates Buy → Buy 05/21/2024 2399.38% HC Wainwright &
Promising Phase 2 Results for Purple Biotech's CM24 in Pancreatic Cancer Treatment Bolster Buy Rating
Purple Biotech Unveils Incentive for Warrant Holders
Purple Biotech Secures $2 Million From Warrants
No Data